公开(公告)号：WO2009157646A9

公开(公告)日：2010-03-04

申请号：PCT/KR2009001916

申请日：2009-04-14

Applicant: BIOBUD CO LTD ,  CHUNG KWANG HOE ,  HONG SUNG YU ,  DOH HYUN JU ,  CHOI JIN SUB ,  LIM JAE HOON ,  KIM SUNG JOONG

Inventor： CHUNG KWANG HOE ,  HONG SUNG YU ,  DOH HYUN JU ,  CHOI JIN SUB ,  LIM JAE HOON ,  KIM SUNG JOONG

IPC: B82B3/00

CPC classification number: G01N33/4905

Abstract: The present invention relates to a production method for an epoxy substrate exhibiting a nanopattern, comprising the stages of: (a) forming a titanium oxide film by anodization of a titanium substrate; (b) obtaining a titanium substrate having a concave shape formed on its surface by removing the titanium oxide film from the titanium substrate on which the titanium oxide film has been formed; (c) coating an epoxy resin onto the titanium substrate on which the concave shape has been formed; and (d) obtaining an epoxy substrate formed with a nanopattern of convex surfaces by removing the titanium substrate. In the production method of the present invention, an epoxy substrate formed with a nanopattern of convex surfaces is produced after anodizing titanium, coating an epoxy resin onto a nanopattern formed with a concave shape on the titanium surface, and removing the titanium substrate. This straightforward process makes it possible to efficiently produce an epoxy resin exhibiting a nanopattern for the measurement of blood coagulation formed with a fine pattern which is uniform and on the nano scale. Further, the epoxy substrate produced by means of the present invention makes it possible to efficiently use an electrochemical technique to ascertain whether or not blood coagulation is present in a blood sample.

Abstract translation: 本发明涉及一种表现出纳米图案的环氧树脂基板的制造方法，其特征在于，包括：（a）通过钛基板的阳极氧化而形成氧化钛膜; （b）从形成有氧化钛膜的钛基板上除去氧化钛膜，得到表面形成有凹形状的钛基板; （c）将环氧树脂涂布到已经形成凹形的钛基板上; 和（d）通过除去钛基材得到形成有凸面的纳米图案的环氧树脂基材。 在本发明的制造方法中，在阳极氧化钛之后，在钛表面上涂布环氧树脂到形成为凹形的纳米图案上，并除去钛基板，制作形成有凸面的纳米图案的环氧树脂基板。 这种直接的方法使得可以有效地制备出显示用于测量均匀且纳米尺度的精细图案形成的凝血的纳米图案的环氧树脂。 此外，通过本发明制造的环氧树脂基板使得可以有效地使用电化学技术来确定血液样品中是否存在凝血。

公开(公告)号：WO2009084841A3

公开(公告)日：2009-09-17

申请号：PCT/KR2008007605

申请日：2008-12-23

Applicant: BIOBUD CO LTD ,  SOHN YOUNG-DOUG ,  KIM BUM JOON ,  KIM OK HWAN ,  KIM KYOUNG JUN ,  SHIN JI HUN ,  HONG SUNG YU ,  HWANG JAE HOON ,  CHUNG KWANG HOE

Inventor： SOHN YOUNG-DOUG ,  KIM BUM JOON ,  KIM OK HWAN ,  KIM KYOUNG JUN ,  SHIN JI HUN ,  HONG SUNG YU ,  HWANG JAE HOON ,  CHUNG KWANG HOE

IPC: C12N9/64

CPC classification number: C12N9/6418 ,  C07K2319/02

Abstract: The present invention relates to a batroxobin-encoding nucleotide sequence and/or a mutated a-factor secretion signal sequence, and a vector and a transformant using the same. The batroxobin-encoding nucleotide sequence of this invention exhibits an excellent expression efficiency in yeast, particular Pichia pastoris and the recombinant batroxobin is obtained at 4-13 fold higher yield than natural-occurring batroxobin-encoding sequences. The protein expression system which uses the batroxobin-encoding nucleotide sequence as well as mutated a-factor secretion signal peptide sequence of this invention obtains the recombinant batroxobin at about 20-fold higher yield than natural-occurring batroxobin-encoding sequences. In addition, the recombinant batroxobin prepared using the sequence of this invention has a significantly plausible activity and stability compared with natural-occuring batroxobin.

Abstract translation: 本发明涉及编码巴曲酶的核苷酸序列和/或突变的α-因子分泌信号序列，以及使用其的载体和转化体。 本发明的巴曲酶编码核苷酸序列在酵母，特别是巴斯德毕赤酵母中表现出优异的表达效率，并且以比天然存在的巴曲酶编码序列高4-13倍的产率获得重组巴曲酶。 使用本发明的巴曲酶编码核苷酸序列以及突变的α-因子分泌信号肽序列的蛋白质表达系统以比天然存在的巴曲酶编码序列高约20倍的产量获得重组巴曲酶。 此外，与天然存在的巴曲酶相比，使用本发明的序列制备的重组巴曲酶具有显着合理的活性和稳定性。

公开(公告)号：WO2004081023A1

公开(公告)日：2004-09-23

申请号：PCT/KR2004/000529

申请日：2004-03-12

Applicant: BIOBUD CO. LTD. ,  HYUNDAI PHARM. IND. CO., LTD. ,  JUNG, In-Hak ,  KANG, Seung-Woo ,  HONG, Sung-Yu ,  KANG, Soo-Jung ,  KOH, You-Seok ,  CHUNG, Kwang-Hoe

Inventor： JUNG, In-Hak ,  KANG, Seung-Woo ,  HONG, Sung-Yu ,  KANG, Soo-Jung ,  KOH, You-Seok ,  CHUNG, Kwang-Hoe

IPC: C07H15/203

CPC classification number: C07C49/255

Abstract: A method for solubilization of curcumin and a water-soluble curcumin prepared by this method are disclosed. The method prepares a water-soluble curcumin by covalent-bonding sugar to the curcumin, thereby making the curcumin, which was insoluble to water, into a water-soluble curcumin. This water-soluble curcumin may be applied to more fields such as food, soluble drugs and dyes.

Abstract translation: 公开了通过该方法制备的姜黄素和水溶性姜黄素的增溶方法。 该方法通过将糖共价键合到姜黄素中制备水溶性姜黄素，由此将不溶于水的姜黄素制成水溶性姜黄素。 这种水溶性姜黄素可用于更多领域，如食品，可溶性药物和染料。

公开(公告)号：WO2003018065A1

公开(公告)日：2003-03-06

申请号：PCT/KR2001/001461

申请日：2001-08-29

Applicant: CHUNG, Kwang-Hoe ,  PARK, Yong-Serk ,  KIM, Soo-In ,  HONG, Sung-Yu ,  SOHN, Young-Doug ,  JANG, Yang-Soo ,  HUN, Chin-Kyu ,  KIM, Doo-Sik

Inventor： CHUNG, Kwang-Hoe ,  PARK, Yong-Serk ,  KIM, Soo-In ,  HONG, Sung-Yu ,  SOHN, Young-Doug ,  JANG, Yang-Soo ,  HUN, Chin-Kyu ,  KIM, Doo-Sik

IPC: A61K48/00

CPC classification number: C12N15/88 ,  A61K9/127 ,  A61K48/00 ,  A61K48/0025 ,  C07K14/46 ,  C12N15/86 ,  C12N2750/14143

Abstract: The present invention relates to liposome complex comprising a novel disintegrin, saxatilin, gene derived from Agkistrodon saxatilis and methods for curing and preventing tumors by transferring the complexes to a living body.

Abstract translation: 本发明涉及脂质体复合物，其包含新颖的解联蛋白，萨克西汀，源自Ag蛇毒素的基因，以及通过将复合物转移到活体来固化和预防肿瘤的方法。

公开(公告)号：WO2012060607A3

公开(公告)日：2012-08-23

申请号：PCT/KR2011008248

申请日：2011-11-01

Applicant: UNIV YONSEI IACF ,  HEO JI HOE ,  KWON IL ,  KIM YOUNG DAE ,  HONG SUNG YU

Inventor： HEO JI HOE ,  KWON IL ,  KIM YOUNG DAE ,  HONG SUNG YU

IPC: A61K38/06 ,  A61P9/00 ,  A61P9/10

CPC classification number: C07K14/001 ,  A61K38/06 ,  A61K38/1703 ,  C07K7/06 ,  C07K14/46 ,  C12N9/6489

Abstract: The present invention relates to: a composition for dissolving thrombi comprising a peptide comprising the Arg-Gly-Asp motif; a pharmaceutical composition for treating stenotic or occlusive vascular diseases which comprises the same; and a thrombus dissolving method and a method for treating stenotic or occlusive vascular diseases, comprising the step of administering the same. The compositions and methods of the present invention have the advantage that they effectively break down already formed thrombi by adopting the principle of targeting integrin within the thrombus such as platelet surface GPIIb-IIIa, which is not the same as the existing principle of plasminogen activation. Also, the compositions and methods of the present invention have a nerve-protecting function as they effectively open as far as the microvasculature, without the occurrence of restenosis after penetration.

Abstract translation: 本发明涉及：包含含有Arg-Gly-Asp基序的肽的溶解血栓的组合物; 用于治疗狭窄或闭塞性血管疾病的药物组合物，其包含所述药物组合物; 以及用于治疗狭窄或闭塞性血管疾病的血栓溶解方法和方法，所述方法包括施用所述血栓疾病的步骤。 本发明的组合物和方法具有如下优点：通过采用血栓内靶向整联蛋白的原理，例如血小板表面GPIIb-IIIa，其与已有的纤溶酶原激活原理不同，可有效分解已形成的血栓。 而且，本发明的组合物和方法具有神经保护功能，因为它们有效地打开至微血管，而不会在穿透后发生再狭窄。

公开(公告)号：WO2009084841A2

公开(公告)日：2009-07-09

申请号：PCT/KR2008/007605

申请日：2008-12-23

Applicant: BIOBUD CO., LTD. ,  SOHN, Young-Doug ,  KIM, Bum Joon ,  KIM, Ok Hwan ,  KIM, Kyoung Jun ,  SHIN, Ji Hun ,  HONG, Sung Yu ,  HWANG, Jae Hoon ,  CHUNG, Kwang Hoe

Inventor： SOHN, Young-Doug ,  KIM, Bum Joon ,  KIM, Ok Hwan ,  KIM, Kyoung Jun ,  SHIN, Ji Hun ,  HONG, Sung Yu ,  HWANG, Jae Hoon ,  CHUNG, Kwang Hoe

IPC: C12N9/64

CPC classification number: C12N9/6418 ,  C07K2319/02

Abstract: The present invention relates to a batroxobin-encoding nucleotide sequence and/or a mutated α-factor secretion signal sequence, and a vector and a transformant using the same. The batroxobin-encoding nucleotide sequence of this invention exhibits an excellent expression efficiency in yeast, particular Pichia pastoris and the recombinant batroxobin is obtained at 4-13 fold higher yield than natural-occurring batroxobin-encoding sequences. The protein expression system which uses the batroxobin-encoding nucleotide sequence as well as mutated α-factor secretion signal peptide sequence of this invention obtains the recombinant batroxobin at about 20-fold higher yield than natural-occurring batroxobin-encoding sequences. In addition, the recombinant batroxobin prepared using the sequence of this invention has a significantly plausible activity and stability compared with natural-occuring batroxobin.

Abstract translation: 本发明涉及一种编码巴曲酶的核苷酸序列和/或突变的a因子分泌信号序列，以及使用该序列的载体和转化体。 本发明的巴曲酶编码核苷酸序列在酵母，特别是巴斯德毕赤酵母中表现出优异的表达效率，并且以比天然存在的巴曲酶编码序列高出4-13倍的产量获得重组巴曲酶。 使用巴曲酶编码核苷酸序列以及本发明的突变型a因子分泌信号肽序列的蛋白质表达系统获得比天然存在的巴曲酶编码序列高约20倍的重组巴曲酶。 此外，使用本发明的顺序制备的重组巴曲酶与天然发生的巴曲酶相比具有显着似乎合理的活性和稳定性。

公开(公告)号：WO2008102932A1

公开(公告)日：2008-08-28

申请号：PCT/KR2007/002512

申请日：2007-05-23

Applicant: BIOBUD CO., LTD. ,  CHUNG, Kwang Hoe ,  PAK, Chwang Siek ,  HONG, Sung Yu ,  KANG, Soo Jung ,  SOHN, Young Doug ,  HWANG, Jae Hoon ,  CHOI, Eun Bok ,  YON, Gyu Hwan ,  LEE, Hyeon-Kyu ,  YANG, Heui Cheol

Inventor： CHUNG, Kwang Hoe ,  PAK, Chwang Siek ,  HONG, Sung Yu ,  KANG, Soo Jung ,  SOHN, Young Doug ,  HWANG, Jae Hoon ,  CHOI, Eun Bok ,  YON, Gyu Hwan ,  LEE, Hyeon-Kyu ,  YANG, Heui Cheol

IPC: A61K31/47

CPC classification number: A61K31/47

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hyperproliferative vascular disorders, and a pharmaceutical anticancer composition comprising the compound represented by the Formula 1. The present compounds exhibit IC 50 values of less than 0.16 μM for vascular smooth muscle cells and cancer cells to effectively prevent proliferation of vascular smooth muscle cells and cancer cells, thereby ensuring prevention or treatment of hyperproliferative vascular disorders such as arteriosclerosis and restenosis, and cancers.

Abstract translation: 本发明涉及用于预防或治疗过度增殖性血管疾病的药物组合物，以及含有式1表示的化合物的药物抗癌组合物。本发明化合物的IC 50值小于0.16μM， 血管平滑肌细胞和癌细胞，以有效地防止血管平滑肌细胞和癌细胞的增殖，从而确保预防或治疗过度增生性血管疾病如动脉硬化和再狭窄以及癌症。

公开(公告)号：WO1997002286A1

公开(公告)日：1997-01-23

申请号：PCT/KR1996000034

申请日：1996-03-11

Applicant: MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE ,  LEE, Keun-Hyeung ,  HONG, Sung-Yu ,  CHO, Hyun-Sook ,  LEE, Bok-Leul ,  CHUNG, Kwang-Hoe ,  YOON, Jeong-Hyeok ,  OH, Jong-Eun ,  MOON, Hong-Mo

Inventor： MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE

IPC: C07K07/04

CPC classification number: C07K14/43563 ,  A61K38/00

Abstract: The present invention relates to novel antibiotic peptides which possess antibacterial and/or antifungal activities causing no cytotoxicity, and to antibacterial and/or antifungal agents containing said peptides as active ingredients. In accordance with the present invention, it has been discovered that: a number of chemically-synthesized peptides which are derived from Tenecin, show superior antibacterial and/or antifungal activities, while causing no untoward effects, and they can be applied for the development of antibacterial and/or antifungal agents.

Abstract translation: 本发明涉及具有不引起细胞毒性的抗细菌和/或抗真菌活性的新型抗生素肽以及含有所述肽作为活性成分的抗菌剂和/或抗真菌剂。 根据本发明，已经发现：从Tenecin衍生的许多化学合成的肽显示出优异的抗菌和/或抗真菌活性，同时不会产生不利影响，并且它们可用于开发 抗菌和/或抗真菌剂。